Literature DB >> 25862894

Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.

Urs Giger-Pabst1, Wiebke Solass2, Bernd Buerkle3, Marc-André Reymond1, Clemens B Tempfer4.   

Abstract

BACKGROUND: Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin is a form of intra-abdominal chemotherapy which can be applied repeatedly and potentially prevents from the systemic side-effects of chemotherapy. CASE REPORT: We present the case of an 84-year-old woman with laparoscopically and histologically confirmed ovarian cancer who refused to undergo systemic chemotherapy. She was treated with eight courses q 28-104 days of low-dose PIPAC with cisplatin at 7.5 mg/m(2) and doxorubicin at 1.5 mg/m(2) at 12 mmHg and 37 °C for 30 min. Objective tumor response was noted, defined as tumor regression on histology, and stable disease noted by peritoneal carcinomatosis index on repeated video-laparoscopy and abdominal computed tomographic scan. The treatment was well-tolerated with no Common Terminology Criteria for Adverse Events (CTCAE) CTCAE >2. With a follow-up of 15 months, the patient is alive and clinically stable. The quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 demonstrated improvement over 5-6 months (global physical score, global health score, global quality of live) without cumulative increase of gastrointestinal toxicity.
CONCLUSION: Low-dose PIPAC is a new form of intraperitoneal chemotherapy which may be applied repeatedly in octogenarian patients. PIPAC may be an alternative and well-tolerated treatment for selected octogenarian patients with ovarian cancer limited to the abdomen who cannot be treated with systemic chemotherapy. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Ovarian cancer; adverse effects; antineoplastic agents; high pressure; intraperitoneal chemotherapy; octogenarian; peritoneal carcinomatosis; quality of life

Mesh:

Substances:

Year:  2015        PMID: 25862894

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Initial Experience from Indian Centers and a Review of Literature.

Authors:  Ninad Katdare; Robin Prabhu; Suniti Mishra; Sanket Mehta; Aditi Bhatt
Journal:  Indian J Surg Oncol       Date:  2018-05-16

Review 2.  Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review.

Authors:  Clemens B Tempfer; Wiebke Solass; Marc-André Reymond
Journal:  Wien Med Wochenschr       Date:  2014-09-24

Review 3.  Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review.

Authors:  Soohyun Oh; Haerin Paik; Soo Jin Park; Eun Ji Lee; Hee Seung Kim
Journal:  Gland Surg       Date:  2021-03

Review 4.  [PIPAC and HIPEC-competing or supplementary therapeutic procedures for peritoneal metastases].

Authors:  H Leebmann; P Piso
Journal:  Chirurg       Date:  2018-09       Impact factor: 0.955

5.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.

Authors:  Giorgi Nadiradze; Urs Giger-Pabst; Juergen Zieren; Dirk Strumberg; Wiebke Solass; Marc-André Reymond
Journal:  J Gastrointest Surg       Date:  2015-10-28       Impact factor: 3.452

6.  Overall clinical and trichoscopic analysis performed in patients who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis - initial trial preliminary report.

Authors:  Maciej Nowacki; Katarzyna Nowacka; Iwona Głowacka; Barbara Zegarska; Wojciech Zegarski
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

Review 7.  Pressurized intraperitoneal aerosol chemotherapy: a review of the introduction of a new surgical technology using the IDEAL framework.

Authors:  S J Tate; J Torkington
Journal:  BJS Open       Date:  2020-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.